ketesse 50 mg/2 ml sol ijf
menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica
nebilet hctz 5 mg/12,5 mg
menarini international operations luxembourg s.a., luxembursko - nebivolol a tiazidy - 58 - hypotensiva
nebilet hctz 5 mg/25 mg
menarini international operations luxembourg s.a., luxembursko - nebivolol a tiazidy - 58 - hypotensiva
dexadol 12,5 mg gro por
menarini international operations luxembourg s.a., luxembursko - dexketoprofén - 07 - analgetica, antipyretica
ketesse 12,5 mg gro por
menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica
ketesse 25 mg gro por
menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica
ketesse 25 mg perorálny roztok vo vrecku
menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica
pulmocis
cis bio international, francúzsko - technécium (99mtc) makrosalb - 88 - radiopharmaca
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - viacnásobný myelóm - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.